Clonal hematopoiesis in human aging and disease

Science, Год журнала: 2019, Номер 366(6465)

Опубликована: Окт. 31, 2019

As people age, their tissues accumulate an increasing number of somatic mutations. Although most these mutations are little or no functional consequence, a mutation may arise that confers fitness advantage on cell. When this process happens in the hematopoietic system, substantial proportion circulating blood cells derive from single mutated stem This outgrowth, called "clonal hematopoiesis," is highly prevalent elderly population. Here we discuss recent advances our knowledge clonal hematopoiesis, its relationship to malignancies, link nonmalignant diseases aging, and potential impact immune function. Clonal hematopoiesis provides glimpse into selection likely occurs all tissues.

Язык: Английский

---

The central role of DNA damage in the ageing process

Nature, Год журнала: 2021, Номер 592(7856), С. 695 - 703

Опубликована: Апрель 28, 2021

Язык: Английский

---

Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells

Nature reviews. Cancer, Год журнала: 2019, Номер 19(10), С. 553 - 567

Опубликована: Авг. 27, 2019

Язык: Английский

---

Advances in molecular classification and precision oncology in hepatocellular carcinoma

Journal of Hepatology, Год журнала: 2020, Номер 72(2), С. 215 - 229

Опубликована: Янв. 15, 2020

Язык: Английский

---

Tobacco smoking and somatic mutations in human bronchial epithelium

Nature, Год журнала: 2020, Номер 578(7794), С. 266 - 272

Опубликована: Янв. 29, 2020

Язык: Английский

---

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

Annals of Oncology, Год журнала: 2022, Номер 33(8), С. 750 - 768

Опубликована: Июль 6, 2022

•Validated and sensitive ctDNA assays can be used to genotype advanced cancers select patients for targeted therapies.•Initial genotyping with should considered when rapid results are needed, tissue is unavailable.•ctDNA assay limited by false-negative results, lower sensitivity fusion events copy number changes.•Use of detect molecular residual disease not recommended, due lack evidence its clinical utility. Circulating tumour DNA (ctDNA) conducted on plasma rapidly developing a strong base use in cancer. The European Society Medical Oncology convened an expert working group review the analytical validity utility assays. For cancer, validated adequately have identifying actionable mutations direct therapy, may routine practice, provided limitations taken into account. Tissue-based testing remains preferred test many cancer patients, detecting changes, although routinely faster will clinically important, or biopsies possible inappropriate. Reflex following non-informative result, testing. In treated early-stage cancers, detection relapse, has high anticipating future relapse cancers. Molecular disease/molecular cannot recommended as currently there no directing treatment. Additional potential applications assays, under research development include responding therapy early dynamic changes levels, monitoring resistance before progression, screening asymptomatic people Recommendations reporting made.

Язык: Английский

---

Somatic mutation landscapes at single-molecule resolution

Nature, Год журнала: 2021, Номер 593(7859), С. 405 - 410

Опубликована: Апрель 28, 2021

Язык: Английский

---

Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring

Nature Medicine, Год журнала: 2020, Номер 26(7), С. 1114 - 1124

Опубликована: Июнь 1, 2020

Язык: Английский

---

Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics

Nature Reviews Genetics, Год журнала: 2020, Номер 22(1), С. 3 - 18

Опубликована: Авг. 17, 2020

Язык: Английский

---

The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic

Nature, Год журнала: 2020, Номер 586(7827), С. 133 - 138

Опубликована: Июль 29, 2020

Язык: Английский

---